目的 比较培美曲塞或多西他赛联合顺铂一线治疗突变状态未知的晚期肺腺癌的临床疗效、反应及生存期。方法 70例晚期肺腺癌患者，分别应用PP组(培美曲塞+顺铂)及DP组(多西他赛+顺铂)治疗。PP组35例，第1天静脉注射培美曲塞500 mg/m2;DP组35例，第1天静脉注射多西他赛75 mg/m2。第2~4天两组均联合顺铂25 mg/m2静脉滴注。21 d为1个周期，每例至少完成2周期后评价疗效及不良反应。结果 PP组中位无进展生存期8个月，中位生存时间14.3个月，1年生存率62.8%。DP组中位无进展生存期7个月，中位生存时间13.3个月，1年生存率65.7%。两组比较差异均无统计学意义。PP组血液学、消化道和肾功能毒性发生率明显低于DP组(P<0.05)。结论 PP或DP一线治疗晚期肺腺癌疗效相当，PP组不良反应较低，适合对于化疗耐受性不佳的患者。
Abstract
Objective To compare toxicity and survival of the clinical curative effect of pemetrexed combined with cisplatin and docetaxel combined with cisplatin in the first-line treatment of advanced lung adenocarcinoma with unknown mutations. Methods 70 patients with advanced lung adenocarcinoma, using PP regimen group (pemetrexed + cisplatin) and DP regimen group(docetaxel + cisplatin) treatment respectively. To PP group of 35 cases, intravenous injection of pemetrexed 500 mg/m2 was given on the first day to DP group of 35 cases, on the first day intravenous docetaxel 75 mg/m2 was given. On 2-4 days, the two groups were given combination of cisplatin intravenous infusion of 25 mg/m2. The curative effects and adverse reactions were evaluated 21 days for a cycle, each patient completed at least 2 cycles. Results The median progression free survival was 8 months, and the median survival time was 14.3 months, and the 1 year survival rate was 62.8% in the PP group. The median progression free survival was 7 months, and the median survival time was 13.3 months, and the 1 year survival rate was 65.7% in the DP group. There was no significant difference between the two groups. The incidence of toxicity of hematology, digestive tract and renal function was significantly lower in PP group than in DP group (P<0.05). Conclusions The effect of PP or DP in the treatment of advanced lung adenocarcinoma is similar and the side effect of PP is lower, which is suitable for patients with poor tolerance to chemotherapy.
关键词
培美曲塞 /
多西他赛 /
肺腺癌 /
疗效 /
不良反应
Key words
pemetrexed /
docetaxel /
lung adenocarcinoma /
effect /
toxicity
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Eisenhauer A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009,45(2):228-247.
[2] Navada S, Lai P, Schwartz AG, et al. Temporal trends in small cell lung cancer:analysis of the national surveillance,epidemiology,and end-results(SEER)database [J]. J Clin Oncol, 2006, 24 (18Suppl): 7082.
[3] Ginsberg R J, Goldberg M, Waters P E. Surgery in non-small lung cancer//Roth J A, Ruckdeschel J C, Weisenburger T H. Thoracic Oncology [M]. 2nd ed. Philadelphia: W.B. Saunders Company, 1995:124-146.
[4] Alberti W,Anderson G, Bartolucci A.Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials [J]. BMJ, 1995, 311(7010): 899-909.
[5] Grossi F, Aita M, Defferrari C,et al. Impact of third-genenration drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach [J]. Oncologist, 2009,14(5):497-510.
[6] Adjei A A. Pemetrexed(ALJMTA):a novel multitargeted antineoplastic agent [J]. Clin Cancer Res, 2004,10(2):4276-4280.
[7] Scagliotti G V, Parikh P, Joachim V P, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [J]. J Clin Oncol, 2008, 26(21): 3543-3551.
[8] Le Chevalier T, Berille Z, Zaleberg J R, et al. Overview of docetaxel(Taxotere)/cisplain combination in non small cell lung cancer [J]. Semin Oncol, 1999, 26(3 Suppl 11): 13-18.
[9] Fossella F, Pereira J R, Von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinationgs versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group [J]. J Clin Oncol, 2003, 21(16): 3016-3024.
[10] Pereira J R, Cheng R, Orlando M, et al. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer [J]. Drugs R D, 2013, 13(4):289-296.
PDF(691 KB)
